The NEOSETAC project will demonstrate the therapeutic anti-cancer potential of a novel Selenium-based therapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancer treatment so far has been limited to chemoprevention as dietary supplement. NEOSETAC aimS to improve the therapeutic window, pharmacokinetic properties, and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradable NPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Se compounds at desired locations (tumor lesions and metastasis) is achieved. Furthermore, NPs are functionalized by cancer cell / cancer stem cell targeting ligands, to further improve the therapeutic efficacy, and to prevent cancer recurrence after chemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover, targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se.
ADSI provides know-how in the designing of preclinical studies.
Total volume: 504,000.- Euro (ADSI share 36,000.- Euro)
Duration: 01/2018 – 12/2022